文献速递糖尿病

血浆肾上腺素参与实验性低血糖相关自主神经衰竭的发生

Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究探讨低血糖时血浆肾上腺素升高是否参与低血糖相关自主神经衰竭(HAAF)的发生及个体易感性差异。24名成人非糖尿病患者接受两次2小时高胰岛素低血糖钳夹(最低54 mg/dL)后次日重复,另7名接受肾上腺素或盐水输注后行阶梯低血糖钳夹。结果显示肾上腺素输注可复现HAAF关键特征,且首次低血糖时肾上腺素反应较高者更易发生HAAF。

要点

  • 低血糖时肾上腺素反应较高者更易发生HAAF。
  • 肾上腺素输注可降低后续低血糖时的肾上腺素反应和症状。
  • 个体间肾上腺素反应差异可解释HAAF易感性不同。

核心结论

  • 血浆肾上腺素升高可复现非糖尿病受试者HAAF的关键特征。
  • 低血糖时肾上腺素反应的显著个体间变异可能解释HAAF易感性差异。

研究设计与样本

  • 24名成人非糖尿病患者接受两次2小时高胰岛素低血糖钳夹(最低54 mg/dL,0-2小时和4-6小时)于第1天,第2天重复第三次相同钳夹。
  • 另7名受试者第1天接受两次2小时肾上腺素输注(0.03 μg/kg/min,0-2小时和4-6小时)对比盐水,第2天行200分钟阶梯低血糖钳夹(90、80、70、60 mg/dL)。

主要发现

  • 发生HAAF者第一次低血糖发作最后30分钟平均肾上腺素水平为未发生者的2.3倍(P = 0.006)。
  • 与盐水相比,第1天肾上腺素输注使第2天70和60 mg/dL血糖阶梯合并的肾上腺素反应降低27%(P = 0.04),低血糖症状平行降低(P = 0.03)。

关键数值与推荐

  • HAAF定义:第三次相比第一次低血糖发作最后30分钟平均肾上腺素水平降低≥20%(P < 0.001)。
  • 肾上腺素输注剂量:0.03 μg/kg/min,两次2小时输注(0-2小时和4-6小时)。
  • 低血糖钳夹最低血糖:54 mg/dL;阶梯低血糖钳夹目标:90、80、70、60 mg/dL。

临床怎么用

  • 低血糖时肾上腺素反应较高者可能更易发生HAAF,需关注个体化低血糖防护。
  • 反复低血糖可钝化肾上腺素反应和症状,临床应减少医源性低血糖暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent hypoglycemia blunts counter-regulatory responses to subsequent hypoglycemic episodes, a syndrome known as hypoglycemia-associated autonomic failure (HAAF). Since adrenergic receptor blockade has been reported to prevent HAAF, we investigated whether the hypoglycemia-associated rise in plasma epinephrine contributes to pathophysiology and reported interindividual differences in susceptibility to HAAF. METHODS: To assess the role of hypoglycemia-associated epinephrine responses in the susceptibility to HAAF, 24 adult nondiabetic subjects underwent two 2-hour hyperinsulinemic hypoglycemic clamp studies (nadir 54 mg/dL; 0-2 hours and 4-6 hours) on Day 1, followed by a third identical clamp on Day 2. We challenged an additional 7 subjects with two 2-hour infusions of epinephrine (0.03 μg/kg/min; 0-2 hours and 4-6 hours) vs saline on Day 1 followed by a 200-minute stepped hypoglycemic clamp (90, 80, 70, and 60 mg/dL) on Day 2. RESULTS: Thirteen out of 24 subjects developed HAAF, defined by ≥20% reduction in average epinephrine levels during the final 30 minutes of the third compared with the first hypoglycemic episode (P < 0.001). Average epinephrine levels during the final 30 minutes of the first hypoglycemic episode were 2.3 times higher in subjects who developed HAAF compared with those who did not (P = 0.006).Compared to saline, epinephrine infusion on Day 1 reduced the epinephrine responses by 27% at the 70 and 60 mg/dL glucose steps combined (P = 0.04), with a parallel reduction in hypoglycemic symptoms (P = 0.03) on Day 2. CONCLUSIONS: Increases in plasma epinephrine reproduce key features of HAAF in nondiabetic subjects. Marked interindividual variability in epinephrine responses to hypoglycemia may explain an individual's susceptibility to developing HAAF.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lontchi-Yimagou E, Aleksic S, Hulkower R, et al. Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure. J Clin Endocrinol Metab. 2020. PMID: 32915987. doi:10.1210/clinem/dgaa539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。